Literature DB >> 25224277

Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.

Sichen Li1, Reshmi Chowdhury1, Fei Liu1, Arthur P Chou2, Tie Li1, Reema R Mody1, Jerry J Lou1, Weidong Chen1, Jean Reiss3, Horacio Soto2, Robert Prins2, Linda M Liau2, Paul S Mischel4, Phioanh L Nghiemphu1, William H Yong3, Timothy F Cloughesy1, Albert Lai5.   

Abstract

PURPOSE: IDH1/2-mutant gliomas harbor a distinct glioma-CpG island methylation phenotype (G-CIMP) that may promote the initiation and progression of secondary pathway gliomas by silencing tumor-suppressive genes. The potential role of tumor-suppressive microRNAs (miRNA; miR) in this process is not understood. EXPERIMENTAL
DESIGN: To identify potential tumor-suppressive miRNA hypermethylated in glioma, the methylation profiles of IDH1/2(WT) gliomas (n = 11) and IDH1(MUT) glioma (n = 20) were compared by using massively parallel reduced representation bisulfite sequencing (RRBS). The methylation status of selected miRNA was validated by using targeted bisulfite sequencing (BiSEQ) in a large cohort of glioma tissue samples including 219 IDH1(WT) and 72 IDH1/2(MUT) samples. The expression of selected miRNAs was determined by using the TaqMan qPCR. Functional analyses of miR148a were conducted and target genes were identified.
RESULTS: We identify miR148a as a novel, G-CIMP-associated miRNA whose methylation is tightly correlated with IDH1 mutation and associated with improved survival in patients with malignant glioma. We confirm that downregulation of miR148a can occur via DNA methylation. We demonstrate that IDH1 mutation provides a mechanism of miR148a methylation and downregulation, and that restoration of miR148a reduced tumorigenic properties of glioma cells, possibly by targeting DNMT1.
CONCLUSIONS: We identify miR148a as a novel G-CIMP-associated miRNA, and provide results suggesting that miR148a restoration may have therapeutic implications. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224277      PMCID: PMC4233178          DOI: 10.1158/1078-0432.CCR-14-0234

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  49 in total

1.  MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer.

Authors:  Akao Zhu; Jiazeng Xia; Junbo Zuo; Shimao Jin; Hong Zhou; Lubin Yao; Hongyu Huang; Zhijun Han
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

2.  DNA methylation silences miR-132 in prostate cancer.

Authors:  A Formosa; A M Lena; E K Markert; S Cortelli; R Miano; A Mauriello; N Croce; J Vandesompele; P Mestdagh; E Finazzi-Agrò; A J Levine; G Melino; S Bernardini; E Candi
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

3.  A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1.

Authors:  Qing Xu; Yue Jiang; Yu Yin; Qi Li; Jun He; Yi Jing; Yan-Ting Qi; Qian Xu; Wei Li; Bo Lu; Stephen S Peiper; Bing-Hua Jiang; Ling-Zhi Liu
Journal:  J Mol Cell Biol       Date:  2012-08-29       Impact factor: 6.216

Review 4.  The microcosmos of cancer.

Authors:  Amaia Lujambio; Scott W Lowe
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

5.  The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer.

Authors:  Masanobu Takahashi; Miriam Cuatrecasas; Francesc Balaguer; Keun Hur; Yuji Toiyama; Antoni Castells; C Richard Boland; Ajay Goel
Journal:  PLoS One       Date:  2012-10-03       Impact factor: 3.240

6.  A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.

Authors:  Christopher G Duncan; Benjamin G Barwick; Genglin Jin; Carlo Rago; Priya Kapoor-Vazirani; Doris R Powell; Jen-Tsan Chi; Darell D Bigner; Paula M Vertino; Hai Yan
Journal:  Genome Res       Date:  2012-08-16       Impact factor: 9.043

Review 7.  A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion.

Authors:  Heidi G Møller; Andreas P Rasmussen; Hjalte H Andersen; Kasper B Johnsen; Michael Henriksen; Meg Duroux
Journal:  Mol Neurobiol       Date:  2012-10-02       Impact factor: 5.590

8.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.

Authors:  Sevin Turcan; Daniel Rohle; Anuj Goenka; Logan A Walsh; Fang Fang; Emrullah Yilmaz; Carl Campos; Armida W M Fabius; Chao Lu; Patrick S Ward; Craig B Thompson; Andrew Kaufman; Olga Guryanova; Ross Levine; Adriana Heguy; Agnes Viale; Luc G T Morris; Jason T Huse; Ingo K Mellinghoff; Timothy A Chan
Journal:  Nature       Date:  2012-02-15       Impact factor: 69.504

9.  Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.

Authors:  Arthur P Chou; Reshmi Chowdhury; Sichen Li; Weidong Chen; Andrew J Kim; David E Piccioni; Julia M Selfridge; Reema R Mody; Stephen Chang; Shadi Lalezari; Jeffrey Lin; Desiree E Sanchez; Ryan W Wilson; Matthew C Garrett; Bret Harry; Jack Mottahedeh; Phioanh L Nghiemphu; Harley I Kornblum; Paul S Mischel; Robert M Prins; William H Yong; Timothy Cloughesy; Stanley F Nelson; Linda M Liau; Albert Lai
Journal:  J Natl Cancer Inst       Date:  2012-09-03       Impact factor: 11.816

10.  Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.

Authors:  Sichen Li; Arthur P Chou; Weidong Chen; Ruihuan Chen; Yuzhong Deng; Heidi S Phillips; Julia Selfridge; Mira Zurayk; Jerry J Lou; Richard G Everson; Kuan-Chung Wu; Kym F Faull; Timothy Cloughesy; Linda M Liau; Albert Lai
Journal:  Neuro Oncol       Date:  2012-10-31       Impact factor: 13.029

View more
  15 in total

1.  Commercial rodent diets differentially regulate autoimmune glomerulonephritis, epigenetics and microbiota in MRL/lpr mice.

Authors:  Michael R Edwards; Rujuan Dai; Bettina Heid; Thomas E Cecere; Deena Khan; Qinghui Mu; Catharine Cowan; Xin M Luo; S Ansar Ahmed
Journal:  Int Immunol       Date:  2017-06-01       Impact factor: 4.823

2.  The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma.

Authors:  Hon-Kit Andus Wong; Rachid El Fatimy; Courtney Onodera; Zhiyun Wei; Ming Yi; Athul Mohan; Sindhuja Gowrisankaran; Priya Karmali; Eric Marcusson; Hiroaki Wakimoto; Robert Stephens; Erik J Uhlmann; Jun S Song; Bakhos Tannous; Anna M Krichevsky
Journal:  Mol Ther       Date:  2015-04-23       Impact factor: 11.454

3.  Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN.

Authors:  Xiang Xia; Kundong Zhang; Guangtao Luo; Gang Cen; Jun Cao; Kejian Huang; Zhengjun Qiu
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

4.  EZH2-, CHD4-, and IDH-linked epigenetic perturbation and its association with survival in glioma patients.

Authors:  Le Zhang; Ying Liu; Mengning Wang; Zhenhai Wu; Na Li; Jinsong Zhang; Chuanwei Yang
Journal:  J Mol Cell Biol       Date:  2017-12-01       Impact factor: 6.216

5.  Preeclampsia is associated with hypermethylation of IGF-1 promoter mediated by DNMT1.

Authors:  Min Ma; Qiong-Jie Zhou; Yu Xiong; Bin Li; Xiao-Tian Li
Journal:  Am J Transl Res       Date:  2018-01-15       Impact factor: 4.060

Review 6.  Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer.

Authors:  Diego M Marzese; Dave Sb Hoon
Journal:  Expert Rev Mol Diagn       Date:  2015-03-22       Impact factor: 5.225

7.  D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation.

Authors:  Tie Li; Christopher D Cox; Byram H Ozer; Nhung T Nguyen; HuyTram N Nguyen; Thomas J Lai; Sichen Li; Fei Liu; Harley I Kornblum; Linda M Liau; Phioanh L Nghiemphu; Timothy F Cloughesy; Albert Lai
Journal:  Mol Cancer Res       Date:  2018-03-15       Impact factor: 5.852

Review 8.  New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.

Authors:  Lilia Dimitrov; Christopher S Hong; Chunzhang Yang; Zhengping Zhuang; John D Heiss
Journal:  Int J Med Sci       Date:  2015-01-20       Impact factor: 3.738

9.  MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting Neuropilin 1.

Authors:  Kedar Yogi; Epari Sridhar; Naina Goel; Rakesh Jalali; Atul Goel; Aliasgar Moiyadi; Rahul Thorat; Pooja Panwalkar; Atul Khire; Archya Dasgupta; Prakash Shetty; Neelam Vishwanath Shirsat
Journal:  Oncoscience       Date:  2015-03-02

10.  MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer.

Authors:  Xiaoping Wu; Tianchi Liu; Ou Fang; Wenhua Dong; Fengjun Zhang; Lindsey Leach; Xiaohua Hu; Zewei Luo
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.